CORTERIA PHARMACEUTICALS
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
CRF2 Agonist for the Treatment of Worsening Heart Failure
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Corteria Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06815471
- Locations
- 🇺🇸
South Oklahoma Heart Research, LLC, Oklahoma City, Oklahoma, United States
🇬🇪Aleksandre Aladashvili Clinic LLC, Tbilisi, Georgia
🇬🇪LTD "Israeli-Georgian Medical Research Clinic Healthycore", Tbilisi, Georgia
Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure
- Conditions
- Heart FailureHeart Decompensation
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Corteria Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05747820
- Locations
- 🇦🇲
Institute of Cardiology Levon Hovhannisyan, Yerevan, Armenia
🇦🇲Erebuni Medical Center, Yerevan, Armenia
🇧🇦Health Institution Medico Laser, Cardiology ward, Banja Luka, Bosnia and Herzegovina
News
Corteria Pharmaceuticals Advances First-in-Class CRF2 Agonists into Phase 2 Heart Failure and Phase 1 Obesity Trials
Corteria Pharmaceuticals has initiated the CRAFT-WHF Phase 2 trial of COR-1167 in 300 patients with worsening heart failure, targeting an unmet medical need affecting over 20% of heart failure patients.